Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

at September 30, 2010, as compared to $206.8 million at December 31, 2009.  The decrease in cash, cash equivalents and available-for-sale securities of $48.6 million is primarily due to cash used in operations and other net cash uses offset by proceeds of $2.4 million from the exercise of common stock options and ESPP purchases.

Qnexa Regulatory UpdateOn October 28, 2010, we received a Complete Response Letter (CRL) from the FDA regarding the Qnexa NDA.  The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.  At the present time, we are preparing a written response to the FDA's requests for information in the CRL.

"As demonstrated by the results of the two-year SEQUEL study, Qnexa patients continue to see weight loss greater than 10%.  We received the Qnexa CRL on October 28, 2010.  In response to the FDA's requests, we are working to submit the final study report from SEQUEL and address their requests in a written response to the CRL," stated Leland Wilson, chief executive officer of VIVUS. "In addition to the release of the SEQUEL data, in the third quarter of 2010 we announced the sale of MUSE to Meda.  This transaction closed on November 5, 2010.  The MUSE transaction marks the end of an era and I wish to thank the hundreds of employees that have been involved in the MUSE business since its inception and approval in 1996. The balance sheet remains strong and through the remainder of 2010 we are focused on the written response to the CRL for Qnexa, the filing for approval of Qnexa in the European Union and additional phase 3 trial results from avanafil."

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, Qnexa(R), completed phase 3 clinical trials for the treatment of obesity and an NDA was filed and accepted by the F
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... According to a new ... Devices Market (Embolic Protection, Chronic Total Occlusion, Atherectomy, ... Filters, Stents, Balloons and Accessories) - Forecasts to ... Peripheral Vascular Devices Market is expected to reach ... of 7.4% from 2014 to 2019. ...
(Date:6/3/2015)...  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a leading ... surgery (MIS) announced today that surgeons have successfully ... Adoption has risen rapidly with a 150% growth ... the company,s expansion from robotics into the general ... over 45 countries.   The AirSeal ...
(Date:6/3/2015)... , June 3, 2015 PillPack, the pharmacy ... a $50 million round of financing led by CRV ... and Sherpa Ventures. The capital will be used to ... and build retail pharmacies in US markets. ... a better, simpler pharmacy experience that folks absolutely love," ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... , MELBOURNE, Australia, Nov. 18 ... pleased to announce a successful capital raising of A$15.6 ... investors, taking the company,s cash reserves to approximately A$24 ... Orbis, an existing Starpharma shareholder and a highly regarded ...
... Nov. 18 Rules-Based Medicine, Inc. (RBM) today announced it ... Covance Inc. (NYSE: CVD ) that will provide ... technologies and services for use in drug development. Under terms ... third-party provider of multiplexed protein biomarker testing services, and RBM ...
Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... Pittsburgh, PA (PRWEB) June 03, 2015 ... basis can cause discomfort in the back, neck, shoulders ... or other musculoskeletal injuries. In addition, recent research links ... a number of chronic diseases. Fortunately, three inventors from ... than sit at a desk. , They have developed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... to turn back the clock on aging stem cells ... in a fracture every three seconds worldwide, according to ... the right signals could help aging stem cells act ... death and disability associated with a frail framework, Georgia ...
... WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and ... the popular statin Zocor because of an increased risk of ... This risk has been seen among some people taking 80 ... year of treatment, the agency said. In light of this, ...
... winter 2009-2010 was much more widespread than was previously realised, research ... year at the end of the H1N1 flu season showed that ... of the 44 per cent who tested positive had contracted swine ... flu, or had been vaccinated. The research, led by ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, June 8 (HealthDay ... may be available in the United States as soon as this ... for the scans to be of much help for those ... earlier diagnosis, which can be important to people who want to ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- Girls ... explain some cases of autism in families with no history ... a certain number of duplications or deletions of one or ... explained Dr. Christian Schaaf, an assistant professor in the department ...
... The University of Alabama at Birmingham has taken a ... patient care with its acquisition of the first cell-processing workstation ... States. Richard Marchase, Ph.D., vice president for Research ... history of breaking ground in the cell-therapy arena. We are ...
Cached Medicine News:Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 3Health News:Girls May Be More Resistant to Autism Than Boys: Study 4Health News:UAB first in US with cell-processing workstation 2Health News:UAB first in US with cell-processing workstation 3
Reciprocating shaker specifically for platelet bags....
... quantitative determination of progesterone ... Progesterone EIA is ... of competitive binding between ... specimen and progesterone-HRP conjugate ...
... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
... Labcold platelet incubators provide accurate and ... have incorporated all of the same ... are found in the Labcold BS ... levels of product security. An independent ...
Medicine Products: